Trials / Active Not Recruiting
Active Not RecruitingNCT03898479
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata
A Multicenter, Open-Label, Extension Study to Assess the Long-Term Safety and Efficacy of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata
- Status
- Active Not Recruiting
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 1,000 (estimated)
- Sponsor
- Sun Pharmaceutical Industries, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in adult patients with chronic, moderate to severe alopecia areata.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CTP-543 | Twice daily dosing |
Timeline
- Start date
- 2019-04-04
- Primary completion
- 2027-05-01
- Completion
- 2027-06-01
- First posted
- 2019-04-02
- Last updated
- 2025-10-22
Locations
91 sites across 2 countries: United States, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03898479. Inclusion in this directory is not an endorsement.